PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för delgocitinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

17 hits

Bibliografisk träff 2021-02-25

A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment.

Miyagaki T, Okano T, Nakajima K, Mitsuishi S, Kishi A, Miyano K, Takeuchi S, Kadono T.

Dermatol Ther · letter; case reports · DOI 10.1111/dth.14888

Bibliografisk träff 2020-12-30

Current treatments for atopic dermatitis in Japan.

Miyano K, Tsunemi Y.

J Dermatol · review; journal article · DOI 10.1111/1346-8138.15730

Bibliografisk träff 2020-12-02

Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.

Anagawa-Nakamura A, Ryoke K, Yasui Y, Shoda T, Sugai S.

Toxicol Pathol · research support, non-u.s. gov't; journal article · DOI 10.1177/0192623320970896

Bibliografisk träff 2020-06-29

Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.

Noji S, Hara Y, Miura T, Yamanaka H, Maeda K, Hori A, Yamamoto H, Obika S, Inoue M, Hase Y, Orita T, Doi S, Adachi T, Tanimoto A, Oki C, Kimoto Y, Ogawa Y, Negoro T, Hashimoto H, Shiozaki M.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.0c00450

Bibliografisk träff 2020-04-01

Delgocitinib: First Approval.

Dhillon S.

Drugs · review; journal article · DOI 10.1007/s40265-020-01291-2

Bibliografisk träff 2020-02-03

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.

Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T.

J Am Acad Dermatol · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.1016/j.jaad.2019.12.015

Bibliografisk träff 2019-12-20

Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.

Yamamoto Y, Otsuka A, Nakashima C, Ishida Y, Honda T, Egawa G, Amano W, Usui K, Hamada Y, Wada M, Tanimoto A, Konishi N, Hayashi M, Matsushita M, Kabashima K.

J Dermatol Sci · letter · DOI 10.1016/j.jdermsci.2019.12.008

Bibliografisk träff 2019-12-09

Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.

Nakagawa H, Nemoto O, Igarashi A, Saeki H, Murata R, Kaino H, Nagata T.

J Dermatol · clinical trial, phase iii; research-article; journal article · DOI 10.1111/1346-8138.15173

Bibliografisk träff 2019-11-08

Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study.

Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TSS.

Br J Dermatol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/bjd.18469

Bibliografisk träff 2019-08-16

Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.

Nakagawa H, Nemoto O, Igarashi A, Saeki H, Oda M, Kabashima K, Nagata T.

J Allergy Clin Immunol · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.jaci.2019.08.004

Bibliografisk träff 2018-04-17

Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.

Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N.

J Dermatol · comparative study; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/1346-8138.14322

Bibliografisk träff 2018-01-15

Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.

Nakagawa H, Nemoto O, Igarashi A, Nagata T.

Br J Dermatol · clinical trial, phase ii; comparative study; multicenter study; randomized controlled trial; journal article · DOI 10.1111/bjd.16014

Bibliografisk träff 2017-07-03

A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents.

Tanimoto A, Shinozaki Y, Yamamoto Y, Katsuda Y, Taniai-Riya E, Toyoda K, Kakimoto K, Kimoto Y, Amano W, Konishi N, Hayashi M.

Exp Dermatol · comparative study; journal article · DOI 10.1111/exd.13370

Bibliografisk träff 2016-09-13

JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation.

Amano W, Nakajima S, Yamamoto Y, Tanimoto A, Matsushita M, Miyachi Y, Kabashima K.

J Dermatol Sci · journal article · DOI 10.1016/j.jdermsci.2016.09.007

Bibliografisk träff 2015-11-06

Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis.

Tanimoto A, Shinozaki Y, Nozawa K, Kimoto Y, Amano W, Matsuo A, Yamaguchi T, Matsushita M.

BMC Musculoskelet Disord · research-article; journal article · DOI 10.1186/s12891-015-0802-0

Bibliografisk träff 2015-06-24

The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling.

Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, Dainichi T, Honda T, Otsuka A, Kimoto Y, Yamamoto Y, Tanimoto A, Matsushita M, Miyachi Y, Kabashima K.

J Allergy Clin Immunol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jaci.2015.03.051

Bibliografisk träff 2014-11-12

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo.

Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M.

Inflamm Res · research-article; journal article · DOI 10.1007/s00011-014-0782-9